1 / 20

Mental Health Care Reform in Lithuania: Trends and Financing

Explore the main trends and financing of mental health care in Lithuania, including data on mental disorders, suicides, drug addiction, and the reform of in-patient and outpatient treatment. Learn about relevant mental health acts and programs, staffing in mental health centers, prescription coverage of psychotropics, and expenses related to in-patient psychiatric treatment.

earlined
Download Presentation

Mental Health Care Reform in Lithuania: Trends and Financing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MENTAL HEALTH CARE REFORM IN LITHUANIA: THE MAIN TRENDS AND FINANCING Ona Davidonienė State Mental Health Centre

  2. MENTAL DISORDERS IN LITHUANIA (per 100 000) Data of State Mental Health Centre of Lithuania

  3. SUICIDES IN LITHUANIA 1930-1940 AND 1986-2001(per 100 000)

  4. SUICIDES IN URBAN AND RURAL AREASIN LITHUANIA 1930-1940 AND 1980-2001(per 100 000)

  5. GROWTH OF DRUG ADDICTION MORBIDITY INLITHUANIA(per 100 000) Data of State Mental Health Centre of Lithuania

  6. MENTAL HEALTH CARE REFORM Pre-reform state Reform target In-patient treatment In-patient treatment Reform Outpatient treatment Outpatient treatment

  7. MENTAL HEALTH ACTS AND PROGRAMMES • Mental Health Care Act (1995) (http://www.vpsc.lt). • (Amendments made in 2001). • Narcotic and Psychotropic Substances Control Act (1998) (http://www.vpsc.lt). • State Programme on Mental Disease Prevention (1999) (http://www.vpsc.lt). • National Drug Control and Drug Use Prevention Programme (approved in 1999). • State Alcohol Control Programme (approved in 1999).

  8. MENTAL HEALTH CENTRES STAFF IN LITHUANIA Data of State Mental Health Centre of Lithuania

  9. Schizophrenia, schizoaffective disorders (F20; F25) Amisulpride Clozapine Olanzapine Risperidone PRESCRIPTION COVERAGE OF PSYCHOTROPICS IN LITHUANIA 100 % coverage Flupentixol Fluphenazine Haloperidol Trifluoperazine Zuclopenthixol Lithium Trihexyphenidylum

  10. Schizotypal and delusional disorders (F21 - F29) Amisulpride Olanzapine Risperidone 80 % coverage Haloperidol Fluphenazine Trifluoperazine Zuclopenthixol Flupentixol Citalopran Fluvoxamine Lithium Amitriptyline Paroxetine Trihexyphenidylum Fluoxetine Sertraline Moderate and severe affective disorders (F30.2; F31.1-F31.5; F32.1-F32.3; F33.1-F33.3) Citalopran Fluvoxamine Fluoxetine Amitriptyline Paroxetine Sertraline Haloperidol Trifluoperazine Lithium Mirtazapine Reboxetine Trihexyphenidylum Dementia (F00 (G30); F01-F03) Amitriptyline Donepezil Melperone Haloperidol Trifluoperazine Lithium Memantine Tiapridal Trihexyphenidylum

  11. Organic psychotic disorders (F06) 50 % coverage Citalopram Fluoxetine Fluphenazine Fluvoxamine Haloperidol Mirtazapine Paroxetine Trifluoperazine Sertraline Lithium Trihexyphenidylum

  12. EUROPE (NORTH AND SOUTH) – N5A ANTIPSYCHOTIC MARKET Source : IMS Health WinEI Q1/02 (Actual Exchange Rates) Countries and Panels included :- UK; HOLLAND; SWEDEN; POLAND; DENMARK; IRELAND; CZECH REP; GERMANY; FRANCE; SPAIN; ITALY; SWITZERLAND; AUSTRIA; GREECE; PORTUGAL; BELGIUM

  13. NORTH AMERICA – N5A ANTIPSYCHOTIC MARKET Source : IMS Health WinEI Q1/02 (Actual Exchange Rates) Countries and Panels included :- USA; CANADA

  14. LITHUANIA – N5A ANTIPSYCHOTIC MARKET

  15. ATYPICAL ANTIPSYCHOTICS PRESCRIPTION GROWTH OVER TIME *Market Definition = N5A1 Atypical Antipsychotics Markets = USA, UK, Canada, Netherlands, Germany, Italy, Japan Source : IMS Health MIDAS Dataview MAT Q1 2002

  16. PRESCRIPTION MARKET SHARE VS. MAIN COMPETITORS *Market Definition = N5A1 Atypical Antipsychotics Source : IMS Health MIDAS Dataview MAT Q1 2002

  17. PRESCRIPTION COVERAGE EXPENSES IN LITHUANIA

  18. IN-PATIENT PSYCHIATRIC TREATMENT IN LITHUANIA Data of State Mental Health Centre of Lithuania

  19. TOTAL NUMBER OF BEDS IN MENTAL HOSPITALS IN LITHUANIA Data of State Mental Health Centre of Lithuania

  20. NUMBER OF DISABLED DUE TO SCHIZOPHRENIA AND MENTAL RETARDATION IN LITHUANIA Data of State Mental Health Centre

More Related